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Abstract
In a recent issue of Breast Cancer Research, investigators from
the Serra laboratory describe a novel mechanism of transforming
growth factor (TGF)-β tumor suppression. Previously, the authors
discovered that stromal TGF-β signaled through Wnt5a to restrain
pubertal ductal elongation and branching. Here, they show that
inhibition of stromal TGF-β signaling or Wnt5a loss leads to
increased β-catenin transcriptional activity and reduced latency in
mammary tumor models, with tumors displaying a higher proportion
of progenitor cell markers. These findings reveal a novel
intersection of two tumor suppressors with a potent oncogenic
pathway and highlight the need for further study on the role played
by canonical Wnt signaling in breast cancer susceptibility and
subtype.
Rosa Serra has made important contributions to our under-
standing of the role played by transforming growth factor
(TGF)-β in breast throughout her career, and in a recent issue
of Breast Cancer Research she describes a novel mecha-
nism of TGF-β tumor suppression [1]. Early work utilizing
inducible dominant-negative type II receptors (metallothionein-
like promoter–TGF-β dominant negative type II receptor
[MT-DNIIR] and mouse mammary tumor virus long terminal
repeat [MMTV]-DNIIR) to suppress TGF-β signaling
demonstrated that, despite its name, the function of TGF-β
within the mammary gland is one of cell type-specific
restraint. TGF-β signaling within stromal cells restrains lateral
branching, and TGF-β signaling within luminal epithelial cells
restrains alveolar development [2,3]. Recently, the investi-
gators from the Serra laboratory conducted a microarray
analysis to identify genes that were affected by DNIIR
expression, and in so doing they discovered a link between
TGF-β and Wnt5a, which is a member of the Wnt family of
secreted morphogens. They then elegantly combined
genetics with transplantation approaches to establish that
Wnt5a is essential for TGF-β-mediated restraint of ductal
outgrowth and branching [4]. Multiple Wnts are expressed in
breast, and their signaling through canonical (β-catenin
mediated) and noncanonical pathways is critical throughout
mammary development [5]. Although deregulated canonical
signaling induces murine mammary tumors and is implicated
in human breast cancers, Wnt5a appears to act as a breast
tumor suppressor [6,7]. This activity may be related to its
propensity to signal through noncanonical pathways that, in
many settings, antagonize canonical Wnt signaling [7].
Having demonstrated the physiologic function of the TGF-β/
Wnt5a pathway in the mammary gland, the authors next
focused on its role in tumor suppression [1]. When crossed
to MMTV-PyVmT or MMTV-neu transgenic models, MT-DNIIR
and Wnt5a-/- mice developed tumors with increased
proliferation and earlier onset. Wnt5a levels were decreased
in DNIIR tumors, supporting the notion that TGF-β regulates
Wnt5a [1]. Whether Wnt5a expression can rescue the loss
of tumor suppression exhibited by MT-DNIIR mice remains to
be demonstrated. Nonetheless, the possibility that TGF-β
exerts its tumor suppressive effects through Wnt5a suggests
a new route to therapeutically augment TGF-β tumor suppres-
sor function separately from its metastasis-promoting effects.
A second important observation in this study is that inhibition
of TGF-β or loss of Wnt5a increased canonical Wnt
signaling. Previous studies in luminal cells show that TGF-β
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and canonical Wnt signaling produce opposite effects. For
example, upregulation of the canonical Wnt pathway (MMTV-
β-catenin) or inhibition of TGF-β signaling (MMTV-DNIIR)
induces precocious alveologenesis [2,8]. In contrast, stromal
MT-DNIIR or loss of epithelial Wnt5a results in several
phenotypes that are similar to those produced by MMTV-
Wnt1 (hyperbranching, increased vascularization, and stromal
hypertrophy) [3,9]. The experiments conducted by Roarty and
coworkers [1] establish the requirement for Wnt5a within
mammary epithelial cells, but leave open the question of
whether it targets luminal or basal cells. Another recent study
has shown that MMTV-Wnt1 activates canonical signaling in
a paracrine fashion exclusively within K14+ cells [9]. Taken
together, these findings suggest that K14+ cells are the most
likely site of Wnt5a suppression of canonical signaling.
Several groups have shown that MMTV-Wnt1 expands cell
populations expressing K14, Sca1, K6, CD24lo/49fhigh, and
other profiles that have been associated with stem and early
progenitor populations [9-13]. Roarty and coworkers [1] now
show that inhibition of TGF-β and Wnt5a loss result in the
emergence of cells with similar characteristics. These
findings suggest that TGF-β and Wnt5a exert their tumor
suppressive effects by antagonizing the canonical Wnt
pathway and limiting the number of stem cells from which
tumors may arise. What remains to be addressed is whether
this occurs early in development to limit the tumor source, or
later to slow tumor progression. Because MT-DNIIR is
inducible, this can be experimentally addressed [3]. In
support of the former scenario, upregulated canonical
signaling and increased Sca1 expression are already present
in Wnt5a-/- and DNIIR tissue, regardless of expression of the
MMTV-PyVmT or MMTV-neu transgenes. This supports the
concept that an early increase in stem cell number may itself
be a major risk factor for cancer development, and that
studies focusing on canonical Wnt signaling and the factors
that regulate it, such as TGF-β and Wnt5a, warrant further
investigation.
On the other hand, the finding that tumors arising on DNIIR
and Wnt5a-/- genetic backgrounds showed higher rates of
proliferation supports the possibility that TGF-β and Wnt5a
exert their suppressive effects by slowing tumor growth. These
observations illuminate the fact that canonical Wnt signaling is
critical for tumor maintenance and proliferation. Indeed, recent
studies have demonstrated the therapeutic effectiveness of
inhibiting canonical Wnt signaling in tumors initiated by
diverse oncogenes. For example, both 7,12-dimethylbenz(a)-
anthracene/12-O-tetradecanoylphorbol-13-acetate ras-induced
tumors and basaloid hamartomas resulting from Hedgehog
pathway hyperactivity have been shown to regress com-
pletely upon blockade of the Wnt pathway [14,15].
Finally, the studies reported by Roarty and coworkers [1] also
show that genetic background may have as great an effect on
breast cancer subtype as either the cancer cell of origin or the
oncogenic stimulus. Their observations underscore the
concept that genetic and environmental factors that affect
canonical Wnt signaling may influence tumor phenotype. In
sum, the Serra laboratory investigators have discovered a new
mechanism of TGF-β-mediated tumor suppression through
regulation of β-catenin that has exciting implications for our
understanding of tumor susceptibility and heterogeneity.
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